Hepion Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Apr 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 8, 2025
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net loss | $(13,192,420) | $(48,926,042) |
| Other comprehensive income (loss): | ||
| Foreign currency translation | 87,124 | 11,389 |
| Total other comprehensive income (loss) | 87,124 | 11,389 |
| Comprehensive loss | $(13,105,296) | $(48,914,653) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.